Programmed cell death 1 receptor

Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay
Diego A Lema, Ewa Jankowska-Gan, Nan Sethakorn, William Burlingham, Ticiana Leal

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000152; DOI: 10.1136/jitc-2019-000152
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Dmitriy Zamarin, Sven Walderich, Aliya Holland, Qin Zhou, Alexia E Iasonos, Jean M Torrisi, Taha Merghoub, Lewis F Chesebrough, Autumn S Mcdonnell, Jacqueline M Gallagher, Yanyun Li, Travis J Hollmann, Rachel N Grisham, Courtney L Erskine, Mathew S Block, Keith L Knutson, Roisin E O’Cearbhaill, Carol Aghajanian, Jason A Konner

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000829; DOI: 10.1136/jitc-2020-000829
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Christoph Helwig, Isabelle Dussault, Masafumi Ikeda

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000564; DOI: 10.1136/jitc-2020-000564
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Esther Oomen-De Hoop, Cor H. Van der Leest, Samira El Bouazzaoui, Sander Bins, Stijn L. W. Koolen, Stefan Sleijfer, Astrid A. M. Van der Veldt, Reno Debets, Ron H. N. Van Schaik, Joachim G. J. V. Aerts, Ron H. J. Mathijssen

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000586; DOI: 10.1136/jitc-2020-000586
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Haris Babačić, Janne Lehtiö, Yago Pico de Coaña, Maria Pernemalm, Hanna Eriksson

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000204; DOI: 10.1136/jitc-2019-000204
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000696; DOI: 10.1136/jitc-2020-000696
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, Patrick M Forde, Marcus O Butler, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Matthew Taylor, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Jennifer Mataraza, Scott Cameron, Todd M Bauer

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000530; DOI: 10.1136/jitc-2020-000530
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael Overman, Milind Javle, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Al B Benson, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu, Anirban Maitra

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000587; DOI: 10.1136/jitc-2020-000587
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
Ami N Shah, Lisa Flaum, Irene Helenowski, Cesar A Santa-Maria, Sarika Jain, Alfred Rademaker, Valerie Nelson, Dean Tsarwhas, Massimo Cristofanilli, William Gradishar

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000173; DOI: 10.1136/jitc-2019-000173

Main menu

Programmed cell death 1 receptor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Programmed cell death 1 receptor

Pages